Krispy Kreme Inc vs Eli Lilly And Co — how do they compare? Krispy Kreme Inc trades at $3.14 (market cap $537.85M), while Eli Lilly And Co trades at $1,217.59 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2008× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| DNUT | LLY | |
|---|---|---|
Market Cap | $537.85M | $1.08T |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $1.24K |
52-Week Low | $2.92 | $639.43 |
Enterprise Value | $1.78B | $1.13T |
Dividend Yield | 3.47% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.14, down 5.99% with bearish technical signals. The company shows mixed fundamentals with a high P/E ratio of 216.5 but attractive P/S of 0.36 and P/B of 0.87. Recent Q2 2026 earnings showed a narrowed loss of $0.03 per share, beating expectations, while revenue declined 12.8% due to refranchising. CEO Josh Charlesworth emphasized turnaround progress with margin improvement and deleveraging (Bloomberg, August 6, 2026).
The outlook remains challenging with negative net income margins and ROE, though analyst sentiment is cautiously optimistic with 50% buy ratings. Key risks include execution of the turnaround strategy and competitive pressures. The stock presents a speculative opportunity if management can sustain operational improvements and return to profitability.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →